Globus Medical shares fall after revenue guidance stays unchanged
Updated
Updated · MarketWatch · May 8
Globus Medical shares fall after revenue guidance stays unchanged
14 articles · Updated · MarketWatch · May 8
The stock dropped 8.3% to $78.03, even as first-quarter revenue rose to $759.9 million and adjusted earnings reached $1.12 a share, both above analyst estimates.
Globus kept full-year revenue guidance at $3.18 billion to $3.22 billion but raised adjusted earnings guidance to $4.70-$4.80 a share from $4.40-$4.50.
Chief executive Keith Pfeil cited strategy changes in Enabling Technology and ongoing weakness at Nevro, where revenue contribution fell 17% from the fourth quarter of 2025; the shares are down 11% this year.
Why did Globus Medical's stock plummet despite record profits and a raised earnings forecast?
Are widespread lawsuits against spinal cord stimulators a hidden crisis for the entire medical device industry?